Press Releases from AFFiRiS AG (3 total)
AFFIRIS AG: Parkinson's Vaccine – Clinical Results Boost Prospects
VIENNA, Austria, September 07, 2016 — AFFiRiS AG announced today results of AFF008A, a Phase I clinical trial to assess boost immunizations with AFFITOPE® PD01A, an active vaccine against Parkinson's disease (PD). The study was funded by a $1.04 million grant from The Michael J. Fox Foundation for Parkinson's Research.
The "boost" study AFF008A was designed to assess one boost immunization with AFFITOPE® PD01A per patient with regard to safety/tolerability and…
AFFIRIS AG: Parkinson's Vaccine – Clinical Results Boost Prospects
Boost Vaccination Data Encourage Continued Development of AFFiRiS Therapeutic Parkinson's Disease Vaccine against Alpha-Synuclein
• PD01A was Safe and Well Tolerated: Primary Endpoint of Phase I "Boost" Study Met
• Immune Response was Seen in 86% of Patients, Resulting in an Increase of Responder Rate after Boost Immunization
• PD01A-induced Antibodies Preferentially Bind to Fibrilic Alpha-Synuclein (aSyn)
• Data will be Presented at the Poster Tour of Leading Abstracts at the 4th World…
AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
Vienna, 27. May 2009. The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the EU's EUROTRANS-BIO call. The respective project is being carried out in cooperation with German company EMC microcollections GmbH. The aim of atherosclerosis vaccination is to increase the amount of "good" high density lipoprotein cholesterol (HDLc) in the blood and thus reduce the occurrence of harmful fatty deposits in the arteries. Product candidates…
